Richard Adeleke, a doctoral researcher at Cornell University, New York, USA, and his research group have developed a groundbreaking vaccine that could protect people from both COVID-19 and the flu in a single shot. This innovative vaccine is based on a modified version of the vesicular stomatitis virus (VSV), which is engineered to be safe and unable to replicate in the body. The vaccine contains a stabilized spike protein from SARS-CoV-2, the virus that causes COVID-19, and a neuraminidase protein from influenza A virus.
In preclinical tests, the vaccine generated strong immune responses in mice, including high levels of antibodies and T cells that effectively protected them from both viruses. When the vaccinated mice were infectedwith either COVID-19 or influenza, they remained healthy, while unvaccinated mice suffered from severe illness and death. Even more promising, the vaccine was able to protect against different flu strains, indicating it could offer broader and longer-lasting protection compared to current seasonal flu vaccines.
This research is particularly relevant to global public health efforts. Currently, COVID-19 and the flu require separate vaccinations, leading to higher costs, logistical challenges, and lower vaccination rates in many communities. A single vaccine that protects against both diseases could simplify immunization programs, reduce healthcare costs, and improve vaccine accessibility worldwide, especially in low-income countries where vaccine distribution remains a challenge.
Another key advantage of this vaccine is its potential for long-term immunity. Unlike current flu vaccines, which must be updated every year due to rapid viral mutations, this new vaccine uses a more stable viral protein, which could provide broader and more durable protection. This means fewer booster shots and better protection against emerging variants of both viruses. Safety and ease of production are also major benefits.
Unlike traditional flu vaccines, which rely on egg-based production and take months to manufacture, this VSV-based vaccine can be produced quickly and at a large scale, making it highly suitable for emergency responses to future pandemics. If proven effective in human trials, this vaccine could revolutionize global vaccination efforts, making it easier for people to stay protected against two of the most significant viral threats to public health. By combining cutting-edge virology and vaccine technology, Richard Adeleke and his team at Cornell University have laid the foundation for a new era of dual-protection vaccines, bringing us closer to a future where one shot is enough to shield people from multiple infectious diseases.
ALSO READ: Nigeria, seven other countries running out of HIV drugs — WHO warns
and then